Melinta Therapeutics Highlighting Delafloxacin and ESKAPE Candidates in Twelve Presentations at 2014 ICAAC Meeting
04 sept. 2014 10h45 HE
|
Melinta Therapeutics
NEW HAVEN, Conn, Sept. 4, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced that an additional three abstracts have been accepted as
late-breakers at the annual Interscience Conference...
Melinta Therapeutics Bolsters Board of Directors with Appointment of Christopher Kiritsy
14 août 2014 10h38 HE
|
Scienta Communications
NEW HAVEN, Conn, Aug. 14, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced the appointment of Christopher Kiritsy to the Company's
Board of Directors. Mr. Kiritsy is currently president,...
Melinta Therapeutics Reports Top-Line Results Showing Equivalent Exposures after Oral and Intravenous Delafloxacin Administration
11 août 2014 12h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn, Aug. 11, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced top-line results of a Phase 1 clinical study that
demonstrated that the administration of single doses of...
Melinta Therapeutics to Present at Annual JMP Securities Healthcare Conference
17 juin 2014 14h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn, June 17, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced that CEO Mary Szela will be presenting at the annual JMP
Securities Healthcare Conference in New York, NY....
Melinta Therapeutics' Phase 3 Study of I.V. and Oral Delafloxacin has Begun Enrolling Patients with Acute Bacterial Skin and Skin Structure Infections
05 mai 2014 11h27 HE
|
Melinta Therapeutics
NEW HAVEN, Conn, May 5, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced that patient enrollment has commenced in a Phase 3 trial
of oral and intravenous (I.V.) delafloxacin, a...